Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. (Nasdaq: WVE) is a clinical-stage biotechnology company focused on RNA medicines, and its news flow reflects active development across multiple programs and financing activities. Company press releases frequently highlight progress from its PRISM RNA medicines platform, which supports modalities such as RNA interference, RNA editing, splicing, and antisense silencing.
Investors following WVE news can expect regular updates on Wave’s key clinical programs. These include WVE-007, an investigational INHBE GalNAc-siRNA for obesity studied in the INLIGHT trial, where the company has reported dose-dependent reductions in serum Activin E and interim body composition data. News items also cover WVE-006, an RNA editing AIMer for alpha-1 antitrypsin deficiency in the RestorAATion-2 trial, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington’s disease, including data on allele-selective reduction of mutant huntingtin.
Wave’s press releases also address corporate and financial developments, such as public offerings of ordinary shares and pre-funded warrants under its shelf registration statement, quarterly financial results, and updates on expected cash runway. Additional news covers participation in major healthcare and investor conferences, including presentations at the J.P. Morgan Healthcare Conference, ObesityWeek, and other industry events, where the company shares preclinical and clinical data as well as strategic priorities.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory interactions, financing transactions, and corporate presentations related to Wave Life Sciences in one place. For those tracking WVE, it provides a centralized view of how the company’s RNA medicines pipeline and capital strategy evolve over time.
Wave Life Sciences (Nasdaq: WVE) reported Q4 and full-year 2025 results and a business update on Feb 26, 2026. Key points: $602.1M cash (Dec 31, 2025) with runway into 3Q 2028, advancing WVE-007 INLIGHT obesity program with 240 mg and 400 mg data due 1Q 2026, RestorAATion-2 fully enrolled through 600 mg with 400 mg multidose data in 1Q 2026, WVE-008 CTA on track for 2026, and ongoing GSK collaboration milestones.
Financials: 2025 revenue $42.7M, net loss $204.4M, R&D $182.8M. Investor webcast at 8:30 a.m. ET today.
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived for a limited time.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026 to review fourth quarter and full year 2025 financial results and provide business updates.
Investors can access the event via the company’s Investor Events page; an archived webcast will be posted on the Wave Life Sciences website after the live event.
Wave Life Sciences (Nasdaq: WVE) regained full rights to WVE-006, an investigational GalNAc-conjugated RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), and will accelerate its registrational strategy.
Wave plans FDA engagement on a potential accelerated approval pathway with regulatory feedback expected mid-2026. RestorAATion-2 400 mg multidose data remain on track for Q1 2026; 600 mg single and multidose cohort data are expected in 2026. The research collaboration with GSK expanded with a fourth program selected; Wave is eligible for up to $2.8 billion in milestones. Wave expects cash runway into 3Q 2028.
Wave Life Sciences (Nasdaq: WVE) outlined 2026 priorities: accelerate development of WVE-007 (INHBE GalNAc-siRNA) for obesity and advance its RNA editing portfolio. Wave plans a Phase 2a multidose start in 1H 2026, new add-on and post-incretin WVE-007 trials in 2026, and near-term single-dose follow-ups (three-month 400 mg and six-month 240 mg data) expected in Q1 2026. Wave reported single-dose 240 mg data showing fat loss similar to GLP-1 at three months with muscle preservation. RNA editing progress includes RestorAATion-2 updates and a planned WVE-008 CTA filing in 2026. Preliminary cash ~$602M, runway into 3Q 2028. Presentation at J.P. Morgan Jan 13, 2026.
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived on the site for a limited time after the presentation.
Wave Life Sciences (Nasdaq: WVE) priced an underwritten public offering to raise gross proceeds of approximately $350 million.
The offering consists of 15,789,475 ordinary shares at $19.00 per share and, in lieu of shares to certain investors, 2,631,578 pre-funded warrants at $18.9999 each (exercise price $0.0001). Wave granted the underwriters a 30-day option to buy up to an additional 2,763,157 shares. The offering is expected to close on or about December 11, 2025, subject to customary conditions.
Wave Life Sciences (Nasdaq: WVE) commenced an underwritten public offering to raise $250 million of ordinary shares and, for certain investors electing that option, pre-funded warrants to purchase ordinary shares on Dec. 8, 2025.
The company granted the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares and shares underlying pre-funded warrants. Jefferies, Leerink Partners and BofA Securities are joint book-running managers. The offering is subject to market and other conditions and will be made only by prospectus and prospectus supplement filed with the SEC.
Wave Life Sciences (Nasdaq: WVE) reported positive interim Phase 1 INLIGHT data for WVE-007 (INHBE) after a single 240 mg subcutaneous dose in individuals with mean baseline BMI ~32 kg/m2.
At Day 85, WVE-007 produced a 9.4% visceral fat reduction (p=0.02), 4.5% total body fat reduction (3.5 lbs; p=0.07), and a 3.2% lean mass increase (4.0 lbs; p=0.01). Mean Activin E fell >75% and maxed at 78% reduction, supporting once- or twice-yearly dosing. Safety was generally favorable up to 600 mg with no serious TEAEs. Phase 2 planning is underway; further 2026 follow-ups expected.
Wave Life Sciences (Nasdaq: WVE) will announce interim data from the ongoing Phase 1 INLIGHT trial of WVE-007 (INHBE) for obesity on Monday, December 8, 2025. A press release will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. Investors can access the live webcast via the company’s Investor Events page and an archived version will be available after the event.
This announcement covers timing and access for interim clinical data disclosure for WVE-007; no trial results or financial metrics are included in this notice.